FAYEZ SAROFIM & CO - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 204 filers reported holding REATA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 1.1%.

Quarter-by-quarter ownership
FAYEZ SAROFIM & CO ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$3,092,345
+12.1%
30,3290.0%0.01%
+10.0%
Q1 2023$2,757,513
+139.3%
30,3290.0%0.01%
+150.0%
Q4 2022$1,152,199
+51.2%
30,3290.0%0.00%
+33.3%
Q3 2022$762,000
-17.4%
30,3290.0%0.00%0.0%
Q2 2022$922,000
-7.2%
30,3290.0%0.00%0.0%
Q1 2022$994,000
+24.2%
30,3290.0%0.00%
+50.0%
Q4 2021$800,000
-73.6%
30,329
+0.7%
0.00%
-80.0%
Q3 2021$3,031,000
-28.9%
30,1290.0%0.01%
-28.6%
Q2 2021$4,264,000
+41.9%
30,1290.0%0.01%
+27.3%
Q1 2021$3,004,000
-19.4%
30,1290.0%0.01%
-21.4%
Q4 2020$3,725,000
+26.9%
30,1290.0%0.01%
+7.7%
Q3 2020$2,935,000
-37.6%
30,1290.0%0.01%
-40.9%
Q2 2020$4,701,000
+8.1%
30,1290.0%0.02%
-18.5%
Q1 2020$4,349,000
-29.4%
30,1290.0%0.03%
-10.0%
Q4 2019$6,159,000
+154.6%
30,1290.0%0.03%
+150.0%
Q3 2019$2,419,000
-14.9%
30,1290.0%0.01%
-20.0%
Q2 2019$2,843,000
+10.4%
30,1290.0%0.02%
+7.1%
Q1 2019$2,575,000
+52.4%
30,1290.0%0.01%
+40.0%
Q4 2018$1,690,000
-31.4%
30,1290.0%0.01%
-23.1%
Q3 2018$2,463,000
+133.7%
30,1290.0%0.01%
+116.7%
Q2 2018$1,054,00030,1290.01%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
CPMG Inc 2,896,901$291,457,00032.14%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 46,646$4,693,0005.31%
Ikarian Capital, LLC 471,400$47,423,0003.34%
Duquesne Family Office 695,033$69,927,0002.27%
Camber Capital Management LP 685,000$68,918,0002.12%
LBJ Family Wealth Advisors, Ltd. 30,359$3,054,0001.82%
MADDEN SECURITIES Corp 33,127$3,333,0001.80%
Biondo Investment Advisors, LLC 104,120$10,475,0001.80%
Tolleson Wealth Management, Inc. 60,750$6,112,0001.73%
Keel Point, LLC 97,074$9,767,0001.26%
View complete list of REATA PHARMACEUTICALS INC shareholders